8-K
filed January 30, 2024, 6:59 PM ET
CIK 0001860782
M&A
confidence high
sentiment neutral
materiality 0.85
2seventy bio, Inc.: restructuring charge — 2seventy bio sells R&D to Regeneron ($5M), focuses on Abecma; cuts workforce ~14%
2seventy bio, Inc.
- Asset sale to Regeneron for $5M upfront, $10M milestone, royalties; ~160 employees transition; sublease facilities.
- Workforce reduction of ~14%, remaining ~65 employees; one-time restructuring costs ~$8M.
- Expected annual cost savings of ~$150M in 2024 and ~$200M in 2025; cash runway extended beyond 2027.
- CEO Nick Leschly resigns upon closing, becomes Chair; COO Chip Baird named CEO; Victoria Eatwell named CFO.
- Focus exclusively on Abecma with BMS; awaiting ODAC/PDUFA for potential third-line approval in 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Victoria Eatwell was appointed as Chief Financial Officer at 2seventy bio, Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
On January 29, 2024, the Board appointed Victoria Eatwell as the chief financial officer of the Company, effective as of the date of the Closing.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nick Leschly resigned as President and Chief Executive Officer at 2seventy bio, Inc..
- Action
- resigned
- Role
- President and Chief Executive Officer
Exact text from the filing
On January 29, 2024, Nick Leschly informed the Company of his resignation as the Company’s president and chief executive officer effective upon the date of the Closing.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
William D. Baird, III was appointed as President and Chief Executive Officer at 2seventy bio, Inc..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
On January 29, 2024, the Board appointed William D. Baird, III as the president and chief executive officer of the Company, effective as of the date of the Closing.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
2seventy bio, Inc. entered into Purchase Agreement with Regeneron Pharmaceuticals, Inc. valued at $5 million in cash (effective 2024-01-29).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Regeneron Pharmaceuticals, Inc.
- Value
- $5 million in cash
- Effective
- 2024-01-29
Exact text from the filing
On January 29, 2024, 2seventy bio, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”).
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
2seventy bio, Inc. announced a restructuring with charges of approximately $8 million affecting the entire company (approximately 14%).
- Type
- restructuring
- Charge
- approximately $8 million
- Affected area
- the entire company
- Headcount
- approximately 14%
Exact text from the filing
complete by the end of the second quarter of 2024. In connection with the workforce reduction and restructuring, the Company expects to incur one-time costs of approximately $8 million, primarily in the first half of 2024, relating to severance and retention packages and related benefits. The estimates of expenses and cash costs that the Company expects to
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.